Glandular Lesions of the Cervix in Clinical Practice: A Cytology, Histology, and Human Papillomavirus Correlation Study From 2 Institutions
- PMID: 25951104
- DOI: 10.5858/arpa.2014-0633-OA
Glandular Lesions of the Cervix in Clinical Practice: A Cytology, Histology, and Human Papillomavirus Correlation Study From 2 Institutions
Abstract
Context: The Papanicolaou (Pap) test has indisputably decreased cervical cancer mortality, as rates have declined by up to 80% in the United States since its implementation. However, the Pap test is considered less sensitive for detecting glandular lesions than for detecting those of squamous origin. Some studies have even suggested an increasing incidence of cervical adenocarcinoma, which may be a consequence of a relatively reduced ability to detect glandular lesions with cervical cancer screening techniques.
Objective: To evaluate the detection rate of glandular lesions with screening techniques currently used for cervical cancer screening and to provide insight as to which techniques are most efficacious in our study population.
Design: We retrospectively reviewed any available cytology, human papillomavirus (HPV), and histologic malignancy data in patients diagnosed with adenocarcinoma in situ and adenocarcinoma from 2 geographically and socioeconomically disparate hospital systems. Identified patients having had a negative/unsatisfactory Pap test within 5 years of adenocarcinoma in situ or adenocarcinoma tissue diagnosis were considered Pap test screening failures. Patients with negative HPV tests on cytology samples were considered HPV screening failures.
Results: One hundred thirty cases were identified (age range, 22-93 years); 39 (30%) had no Pap history in our files. Eight of 91 remaining cases (8.8%) were screening failures. The detected sensitivity for identifying adenocarcinoma in situ/adenocarcinoma in this study was 91.2% by cytology alone and 92.3% when incorporating HPV testing. The most common cytologic diagnosis was atypical glandular cells (25 cases), and those diagnosed with adenocarcinoma were 7.4 years older than those diagnosed with adenocarcinoma in situ (50.3 versus 42.9 years). Nine of 24 HPV-tested cases (37.5%) were called atypical squamous cell of undetermined significance on cytology.
Conclusions: Our results highlight the importance of combined Pap and HPV cotesting. Although the number of cases identified is relatively small, our data suggest screening for squamous lesions facilitates the recognition of glandular lesions in the cervix. Additionally, increased use of combined Pap and HPV cotesting may decrease detection failure rates with regard to glandular lesions.
Similar articles
-
Squamous cell carcinoma of the cervix: a cytology-histology-human papillomavirus correlation in clinical practice.Arch Pathol Lab Med. 2015 Jun;139(6):776-81. doi: 10.5858/arpa.2014-0202-OA. Arch Pathol Lab Med. 2015. PMID: 26030246
-
History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.Cancer Cytopathol. 2015 Jul;123(7):421-7. doi: 10.1002/cncy.21545. Epub 2015 May 8. Cancer Cytopathol. 2015. PMID: 25955972
-
Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.Cancer Cytopathol. 2016 May;124(5):317-23. doi: 10.1002/cncy.21687. Epub 2016 Jan 15. Cancer Cytopathol. 2016. PMID: 26774025
-
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Vaccine. 2012. PMID: 23199969 Review.
-
Review of Cytology Practice at Thomas Jefferson University Hospital before and after High-Risk Human Papillomavirus Testing.Acta Cytol. 2016;60(6):534-539. doi: 10.1159/000446271. Epub 2016 Jun 2. Acta Cytol. 2016. PMID: 27245463 Review.
Cited by
-
Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.J Natl Cancer Inst. 2018 May 1;110(5):501-508. doi: 10.1093/jnci/djx225. J Natl Cancer Inst. 2018. PMID: 29145648 Free PMC article.
-
Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.Int J Cancer. 2020 Feb 1;146(3):810-818. doi: 10.1002/ijc.32340. Epub 2019 May 6. Int J Cancer. 2020. PMID: 30980692 Free PMC article.
-
Predictors of treatment failure for adenocarcinoma in situ of the uterine cervix: Up to 14 years of recorded follow-up.Oncol Lett. 2022 Aug 25;24(4):357. doi: 10.3892/ol.2022.13477. eCollection 2022 Oct. Oncol Lett. 2022. PMID: 36168314 Free PMC article.
-
Comprehensive profile and contrastive analysis of circular RNA expression in cervical squamous carcinoma and adenocarcinoma.PeerJ. 2023 Jan 26;11:e14759. doi: 10.7717/peerj.14759. eCollection 2023. PeerJ. 2023. PMID: 36721776 Free PMC article.